News Posts List
After a decade of research collaboration, the Atlanta Clinical & Translational Science Institute (ACTSI) will welcome a new partner and change its name, reflecting a new statewide focus. The University of Georgia will officially become the fourth academic partner and ACTSI will now be known as the Georgia Clinical & Translational Science Alliance (Georgia CTSA)
Brussels (Belgium), 21 September 2017 – 18:00 (CEST): UCB today announced that the European Commission (EC) approved expanding the use of its anti-epileptic drug (AED) VIMPAT® (lacosamide) as monotherapy and adjunctive therapy in the treatment of partial-onset seizures (also known as focal-onset seizures (FOS) according to ILAE terminology 5,6) with or without secondary generalisation in adults, adolescents and children from 4 years of age.
Georgia State Partners With American Cancer Society To Support National Tobacco-Free Campus Initiative
ATLANTA—Researchers at Georgia State University’s School of Public Health are partnering with the American Cancer Society (ACS) on a project to help colleges and universities across the United States develop and implement tobacco-free policies.
The United States is the global leader in biomedical innovation, discovering more new cures than the rest of the world combined. We have brilliant scientists, world-class research institutions, and dedicated investors. But what sets us apart is a commitment to free-market policies that reward innovation and recognize the inherent costs and risks of discovering new treatments.
ATLANTA—Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according to a new research study.
ATLANTA—Dr. Benoit Chassaing of Georgia State University’s College of Arts and Sciences has received a $100,000 Innovator Award from the Kenneth Rainin Foundation, part of $3 million awarded for Inflammatory Bowel Disease (IBD) research. The grants will support researchers across the world as they study new ideas that could lead to breakthrough discoveries about IBD. Those who demonstrate significant progress are eligible for additional years of support.
New indication for BRIVIACT® (brivaracetam): UCB’s newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
RIVIACT® CV provides a new monotherapy treatment option for epilepsy patients 16 years of age and older with partial-onset (focal) seizures, which can be initiated at a therapeutic dose at day one. Approval applies a newly established regulatory pathway which allows monotherapy treatment options to reach epilepsy patients sooner. New indication comes just 18 months after launch of BRIVIACT® in the U.S.
FDA commissioner Scott Gottlieb announced Tuesday that the agency will release guidance to close a loophole that allows companies to avoid their obligation to study pharmaceuticals in pediatric populations. The situation, according to Gottlieb, arises if sponsors received an orphan designation for a pediatric subtype of an otherwise common and non-orphaned adult disease.
A Georgia Tech-led research consortium received a nearly $20 million National Science Foundation grant to fund a new engineering research center.
ATLANTA—A nanolaser known as the spaser can serve as a super-bright, water-soluble, biocompatible probe capable of finding metastasized cancer cells in the blood stream and then killing these cells, according to a new research study.
|Neon CRM by Neon One|